Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS

Boost For Lilly, Blow For Pfizer

Executive Summary

Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.

You may also be interested in...



Lilly’s Early Bird Verzenio Goes After Up To S4bn Worm With Early Breast Cancer Nod

Given the requirement for patients to have a Ki-67 score of at least 20%, the challenge now is to alter physicians’ thinking around Ki-67 testing, execs told Scrip.

CDK4/6 Market: Is A Shakeup Underway?

Pfizer's Ibrance still dominates the category but sales slowed in the first quarter, while Novartis’s Kisqali and Lilly's Verzenio both grew double digits.

Pfizer Triples Down On CDK Inhibition In Breast, Other Cancers

Pfizer is looking to address breast cancer resistant to Ibrance and other CDK4/6 inhibitors, but sees potential paths to earlier lines of treatment and additional tumors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel